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Amyloidosis is caused by extracellular deposition of proteins
in an insoluble manner within tissues. In hereditary forms of
amyloidosis, transthyretin, fibrinogen A-a, lysozyme, gelsolin,
apolipoprotein A-I, and A-II accumulate in the tissue plaques.
Here we describe a 52-year-old man with no family history of
renal disease who presented with increased urinary
frequency, gradual loss of renal function but no significant
proteinuria. Renal biopsy found large amounts of amyloid
restricted to the medulla with no involvement of glomeruli or
vessels. Immunohistochemical analysis for transthyretin or
serum amyloid A and tests for an underlying monoclonal
gammopathy were negative. Although initially suspected to
be amyloid light chain amyloidosis, laser microdissection and
mass spectrometry showed that the amyloid was composed
of large amounts of apolipoprotein A-IV. This was based on
mass spectrometry studies that showed 100, 96, and 73
spectra in three microdissected samples that matched to
apolipoprotein A-IV with 100% probability. DNA analyses
detected three sequence variants representing common
polymorphisms of the apolipoprotein A-IV gene. Thus, in this
case, apolipoprotein A-IV deposition and renal involvement
appear to be restricted to the medulla. A high degree of
suspicion is required for the diagnosis of apolipoprotein A-IV
amyloidosis as it may be missed if a renal biopsy consists
only of cortex.
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Amyloidosis is caused by extracellular deposition of proteins
in an insoluble b-pleated format. Amyloid deposits are
identified based on their apple-green birefringence under a
polarized light microscope on Congo red staining and by the
presence of rigid, non-branching fibrils that measure
7.5–10 nm in diameter on electron microscopy.1,2 The most
common forms of systemic amyloidosis are immunoglobulin
light-chain amyloidosis, and reactive secondary amyloidosis
due to chronic inflammatory diseases (e.g., rheumatoid
arthritis and chronic infections). Hereditary forms of
amyloidosis is another group of amyloid that is now being
diagnosed with increasing frequency, and includes amyloid
derived from transthyretins (TTRs), fibrinogen A-a chain,
lysozyme, and apolipoproteins.3–10
Renal apolipoprotein A-I and A-II amyloidosis have
recently been described.4,5 Apolipoprotein A-I amyloidosis
shows extensive involvement of the medulla with tubuloin-
terstitial nephritis,11 whereas apolipoprotein A-II amyloidosis
tends to involve glomeruli and vessels.6,12 Renal apolipopro-
tein A-IV-associated amyloidosis has not been described,
although apolipoprotein A-IV was co-deposited with TTR in
the heart in a case of senile systemic amyloidosis.13,14
Apolipoprotein A-IV is a small 46 kDa glycoprotein that is
primarily synthesized in the small intestine and is important
in the absorption, transport, and metabolism of lipids.14
We describe a unique case of renal amyloidosis confined to
the medulla, and using laser microdissection and mass
spectrometry we show that the amyloid is composed
predominantly of apolipoprotein A-IV.
RESULTS
Case history
A 52-year-old man presented with a 10-year history of
urinary symptoms of frequency and urgency. His primary-
care physician evaluated him through the years. Urinalyses
and prostate-specific antigen were reportedly always within
normal limits. However, even 7 years ago, his serum
creatinine was elevated at 1.7mg/dl, and gradually had
risen to 1.97mg/dl last year at which time he was referred
to a nephrologist. The patient reported an increased
sensation of bladder pain preceding urination. Urinalysis
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was unremarkable. The impression was of stage III chronic
kidney disease of unknown etiology. The patient did not
smoke and his family history was negative for renal disease.
Renal ultrasound with post-void bladder scanning was
unremarkable. Twenty-four hour urine collection showed
no proteinuria. Serum and urine protein electrophoresis and
immunofixation studies were negative for monoclonal
proteins. Free light chain (kappa to lambda) ratio was 1.05.
In addition, parathyroid hormone was normal. Laboratory
values are given in Table 1. At this time, a renal biopsy was
performed.
Renal biopsy findings
Light microscopy. Three cores were received and con-
tained both renal cortex and medulla. There were up to 27
glomeruli present in the sample submitted for light
microscopy; three glomeruli were globally sclerosed. Glo-
meruli with segmental sclerosis were not present. The
glomeruli showed no significant abnormalities; in particular,
there was no hypercellularity, leukocytic infiltrates, or
crescents, and deposits of amorphous, homogeneous, acel-
lular, eosinophilic material were not present in the glomeruli
(Figure 1a). In contrast, the medulla was expanded by
accumulation of acellular, eosinophilic, amorphous material
(Figure 1b). Congo red stain revealed orange-red deposits
limited to the medulla that showed the characteristic apple-
green birefringence of amyloid under polarized light (Figure
1c and d). There was no inflammation in the cortex or in the
medulla. Approximately 10% of the cortical tissue showed
tubular atrophy and interstitial fibrosis. Arteries and
arterioles showed mild sclerosis of the media without any
significant Congo red-positive staining. Immunohistochem-
istry for reactive secondary amyloidosis and transthyretin was
negative.
Immunofluorescence microscopy contained 22 glomeruli,
of which 8 were globally sclerosed. The glomeruli were
negative for immune deposits, including kappa and lambda
light chains. The medulla was also negative for immune
deposits, including kappa and lambda light chains. There was
no staining of fibrinogen in the glomeruli or medulla.
Electron microscopy showed amyloid fibrils in the medulla,
whereas the glomeruli were negative for amyloid fibrils.
The diagnosis was that of renal amyloidosis, undeter-
mined type limited to the renal medulla.
Clinical follow-up. The patient was referred to a hematol-
ogist and a cardiologist. The cardiology evaluation included a
normal electrocardiogram and echocardiogram, with no wall
thickening, no speckling pattern, and a normal left
ventricular ejection fraction of 65%. The patient reported
no cardiac-related symptoms and his cardiovascular physical
exam was within normal limits. He was advised about the
need for regular cardiology follow-up in the setting of
amyloidosis. A bone marrow aspirate and biopsy at this time
showed a normocellular marrow with no evidence of
lymphoproliferative or plasma cell disorder. There was also
no evidence of amyloid in the bone marrow. Six months
following renal biopsy, the patient continued to report
dysuria, but he denied weight loss, diarrhea, constipation,
abdominal pain, macroglossia, difficulty in swallowing,
dizziness, orthostasis, syncope, or paresthesias. The patient
was started on dexamethasone and received the first cycle of
lenalidomide. Autologous stem cell transplantation was
Table 1 | Summary of laboratory findings
Reference range
White blood cell count 6.80 103/ml 3.28–9.29 103/ml
Red blood cell count 4.61 106/ml 4.21–5.6 106/ml
Hemoglobin 14.6 g/dl 12.3–16.3 g/dl
Hematocrit 41.2% 37.4–47%
Platelet count 167 103/ml 143–398 103/ml
Beta-2-microgobulin 2.7mg/dl 1.0–2.1mg/dl
Sodium 142mmol/l 137–145mEq/l
Potassium 4.7mmol/l 3.6–5.4mEq/l
Chloride 105mmol/l 98–110mEq/l
CO2 content 31mmol/l 20–29mmol/l
Glucose 98mg/dl 65–100mg/dl
eGFR 33ml/min 489ml/min
Creatinine 2.1mg/dl 0.5–1.3mg/dl
Urea nitrogen 21mg/dl 7–23mg/dl
Total protein 6.6 g/dl 6.2–8.3 g/dl
Albumin 4.5 g/dl 3.7–5.1 U/l
Total bilirubin 0.5mg/dl 0.2–1.1mg/dl
Alkaline phosphatase 60U/l 31–103U/l
Aspartate transferase 18U/l 7–36U/l
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Figure 1 | Light microscopy. (a, b) Hematoxylin and eosin
( 40)-stained sections showing (a) normal glomerular
morphology and (b) marked interstitial expansion with the
amyloid. (c) Congo red showing reddish orange amyloid material
in the interstitium that shows (d) apple-green birefringence under
polarized light ( 40). (e) Congo red stain showing marked area
for microdissection.
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discussed as the best option for treatment and the patient was
accepted into the transplant program.
Laser microdissection and mass spectrometry. At this time,
the biopsy specimen was sent to the Renal Biopsy Laboratory
Mayo Clinic for work-up and typing of the amyloid. Laser
microdissection (LMD) and mass spectrometry analysis of the
amyloid was performed as previously described.15,16 Briefly,
Congo red-positive regions of the medulla were microdis-
sected by using laser capture techniques (Figure 1e). Peptides
extracted from the microdissected tissue were subjected to
liquid chromatography and tandem mass spectrometry (MS/
MS). The most abundant peptides detected represented
apolipoprotein A-IV protein. MS/MS showed 100, 96, and
73 spectra in three patient samples that matched to
apolipoprotein A-IV. Small amounts of apolipoprotein E,
serum amyloid protein, apolipoprotein A-I, Igg1, Igg2, Igg3,
Iga, kappa and lambda light chains were also detected. LC-
MS/MS failed to detect peptides representing transthyretin,
fibrinogen A-a, serum amyloid A component, or apolipopro-
tein A-II. The results are shown in Figure 2.
Genetic evaluation. Sequencing of the apolipoprotein A-IV
gene was performed. The following three-sequence variants of
the apolipoprotein A-IV gene were detected: c.548G4A,
p.T29T (Thr29Thr) (Figure 3a); c.1678G4A, p.S147N
(Ser147Asn) (Figure 3b); and c.2378G4T, p.Q380H
(Gln380His) (Figure 3c). Sequencing for apolipoprotein A-I
gene was performed. Two sequence variants were detected in
apolipoprotein A-I as follows: c.60T4C, p. H20H (His20His),
and c.209T4C, p. L70P (Leu70Pro).
Final renal biopsy diagnosis. Apolipoprotein A-IVamyloid-
osis involving the renal medulla.
Further follow-up
Eighteen months following the kidney biopsy, the patient is
well, except for his chronic urinary symptoms, including
urgency and pain preceding urination. He is following a low-
sodium, low-protein diet. He continues to work full time and
keeps physically active.
DISCUSSION
We describe a case of renal amyloidosis that was limited to
the medulla. The initial suspicion was that of an amyloid
light-chain amyloidosis. However, subsequent work-up did
not show an underlying gammopathy, and electrophoresis
studies and bone marrow biopsy were negative for an
underlying lymphoproliferative plasma cell disorder. Staining
for serum amyloid A and TTR were also negative on the
kidney biopsy. Subsequent protein analysis by LMD and MS/
MS revealed the amyloid to be composed primarily of
apolipoprotein A-IV.
Hereditary amyloidoses are a group of disorders in which
the amyloid fibrils are derived from genetic variants of TTR,
fibrinogen A-a chain, gelsolin, lysozyme, apolipoprotein A-I,
and apoliporotein A-II. Most cases of hereditary amyloidosis
are autosomal dominant with a typically late adulthood
onset, and many cases do not have a family history of
amyloidosis. Hereditary amyloidosis typically has a slower
rate of progression compared with amyloid light-chain
amyloidosis. The diagnosis of hereditary amyloidosis has
implications for prognosis, genetic counseling, and treat-
ment. A recent study found that almost 10% of the amyloid
light-chain amyloidosis diagnosed by clinical or laboratory
finding with an absence of family history, in fact, had
evidence of an underlying hereditary amyloidosis.17 The most
commonly missed diagnosis was that of fibrinogen A-a chain
and TTR amyloidosis.
Our laboratory has considerable experience with work-up
and diagnosis of amyloidosis using the technique of LMD
and MS/MS, and we have shown that LMD and MS/MS is a
sensitive and specific tool for the diagnosis and typing of
amyloid.15,16 We performed LMD on the medullary tissue to
determine the composition of amyloid. LMD and MS/MS
showed that the amyloid deposits were made of large
amounts of apolipoprotein A-IV, which came as a surprise
to us. MS/MS showed 100, 96, and 73 spectra in three
microdissected samples that matched to apolipoprotein A-IV.
This is a very high number of mass spectra and is indicative
of great abundance and high amino acid sequence coverage
(68% in this case). A high mass spectra value also indicates a
higher confidence in protein identification. It is not
uncommon to find very small amounts of apolipoprotein
E, apolipoprotein A-I and A-IV, and immunoglobulins on
mass spectrometry studies on different types of amyloid.
However, the extensive deposition of apolipoprotein A-IV is
unique in this case, and we have not observed it in any of the
other types of amyloidosis.
Our molecular genetics laboratory has extensive experi-
ence with transthyretin amyloidosis diagnosis by gene
sequencing, and has recently developed sequencing assays
for the fibrinogen-alpha, lysozyme, gelsolinA, apoplipopro-
tein A-I, and apolipoprotein A-II familial amyloidosis
variants. An assay has also been developed for apolipoprotein
A-IV, as this protein has been detected in other cases of
suspected amyloidosis. Although the literature lacks evidence
supporting apolipoprotein A-IV as a genetic disorder, the
possibility for this entity still exists as more cases are
investigated and detected initially through LC MS/MS.
In silico analysis using Alamut v2 (Interactive Biosoftware,
San Diego, CA) indicates that the two-sequence variants in
apolipoprotein-AI and three-sequence variants detected in
apolipoprotein A-IV in our case are common polymorphisms
in the respective genes. Moreover, the c.2378G4T, p.Q380H
alteration has been detected previously in our molecular
genetics laboratory in a case of cardiac amyloid with
apolipoprotein A-IV detected by LC MS/MS (data not
shown). According to the dbSNP reference (rs5110) for the
Q380H alteration, this polymorphism occurs with an allele
frequency of 5–20% depending on the population tested. The
dbSNP references for the other two alterations seen,
c.548G4A, p.T29T, and c.1678G4A, p.S147N, are rs5104
and rs5092, respectively. An allele frequency of 10–40% exists
for the T29T sequence variant, and 5–30% for S147N, also
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depending on the population tested. No allele frequency data
nor dbSNP references are available for the alterations
detected in apolipoprotein A-I; however, our laboratory
experience has demonstrated the H20H alteration in 95% of
cases sequenced thus far, and the L70P in greater than 1%.
Allele frequencies greater than 1% suggest that the sequence
variant occurs with regular frequency in the genome and
population, hence implying that the change is well tolerated
and does not elicit pathogenesis. Furthermore, the H20H
(apolipoprotein A-I) and T29T (apolipoprotein A-IV)
alterations are silent changes (conferring no change in amino
acid) and inherently assumed to be nonpathogenic. The
potential for a splice-site change for all of these variants was
performed, with particular relevance to the H20H and T29T
c
b
APOA4_HUMAN (100%), 45,399.4 Da
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 (sp) (P06727)
26 unique peptides, 33 unique spectra, 96 total spectra, 268/396 amino acids (68% coverage)
a
Figure 2 |Mass spectrometry data. (a) Scaffold readout of top 20 proteins by Spectra. Liquid chromatography and tandem mass
spectrometry (LC-MS/MS) proteomic data are shown from three samples prepared from three separate laser microdissections (LMDs) of
Congo red-positive medullary tissue. The proteomic data show large amount of apolipoprotein A-IV with 100% probability. The probability
number (100% is highlighted by green, 490% by yellow) indicates essentially the percent homology between peptides detected in the
specimens and the published amino acid sequences of their corresponding proteins. (b, c) Sequence coverage shows that peptides in
microdissected sample covers 68% of apolipoprotein A-IV peptide sequence and shows 100% probability of the protein representing
apolipoprotein A-IV.
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(silent) variants in apolipoprotein A-I and apolipoprotein
A-IV, respectively. Results of this analysis further supported
that these changes are benign polymorphisms as no change in
mRNA splicing was noted. Bergstrom et al.13,14 also did not
find any mutations in the nucleotides of the apolipoprotein
A-IV gene cloned from a patient with cardiac amyloid
composed of apolipoprotein A-IV and TTR. Thus far, this is
the extent of our understanding of the genetic alterations in
amyloidosis associated with apolipoprotein A-IV. With time,
some changes detected, which were originally thought to be
benign polymorphisms, may be determined to be pathogenic
as has been seen with other genetic diseases. More cases are
needed to sort out this dilemma.
This is the first report to show amyloidosis associated with
apolipoprotein A-IV in the kidney. The renal involvement
was limited to the medulla and the cortex showed no amyloid
deposition. This is in sharp contrast to the typical renal
amyloid in which the glomeruli, vascular compartment and,
less often, tubulointerstitium are involved. The limitation of
the amyloid to the medulla correlates with the clinical
findings of slow decline of renal function, unremarkable
urinalysis, and no significant proteinuria. The apolipoprotein
A-IV appears similar in this regard to apolipoprotein A-I,
which also involves the medulla, with similar clinical findings
of moderate polyuria and nocturia, suggesting a mild form of
nephrogenic diabetes insipidus.11 Patients with apolipopro-
tein A-1 often show liver disease with deposition of amyloid
in the liver, resulting in abnormal liver function tests; cardiac
amyloidosis is also noted in a few patients. In our patient,
liver and cardiac function was normal, and neither liver nor
cardiac biopsies have been performed to determine whether
there is subclinical involvement of these organs by amyloid. It
is possible that apolipoprotein A-IV-associated amyloid does
not involve the heart and liver. There is no specific therapy
available for apolipoprotein A-IV-associated amyloid. How-
ever, given the long history of renal dysfunction in our
patient, apolipoprotein A-IV amyloid appears to be only very
slowly progressive. Renal transplantation is a likely option
when end-stage renal disease develops.
Studies on apolipoprotein A-I have shown that cleavage of
the full-length protein and generation of an N-terminal
fragment are important steps in amyloidogensis.18,19 Another
study shows that C-terminal amphipathic molecules of
apolipoprotein A-I initially bind to the lipid surface, resulting
in a major conformational change in the N-terminal portion
of the molecule, leading to hydrophobic helix lipid interac-
tions rather than to intramolecular N-terminal hydrophobic
helix–helix interactions that would otherwise occur.20 A
similar mechanism is proposed for apolipoprotein A-IV,
where the N terminus residues of apolipoprotein A-IV are
unfolded and reoriented toward lipid surfaces, resulting in
aggregation of these proteins.13,14 As both apolipoprotein A-I
and apolipoprotein A-IV amyloidosis appear to involve the
renal medulla genetic analysis, immunohistochemistry, and
LMD and MS/MS will be required to differentiate between
these two types of amyloidosis.
To summarize, we report a case of renal apolipoprotein
A-IV-associated amyloid that is limited to the renal medulla
and presents with slowly progressive renal dysfunction. A
high degree of suspicion is required for the diagnosis of
apolipoprotein A-IV amyloidosis and the diagnosis may be
missed if the renal biopsy consists of only renal cortex. As the
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Figure 3 | Sequencing of apolipoprotein A-IV. (a) Left panel: electropherogram of c.548G4A, p.T29T alteration. Segments A and B are the
reference sequence, C and D are the patient’s sequence, and E and F are the subtraction plot between the reference sequence and the
patient. The black arrow indicates the detected alteration. (b) Middle panel: electropherogram of c.1678G4A, p.147S4N alteration.
Segments A and B are the reference sequence, C and D the patient’s sequence, and E and F are the subtraction plot between the reference
sequence and the patient. The black arrows indicate the detected alteration. (c) Right panel: electropherogram of c.2378G4T, p.Q380H
alteration. Segments A and B are the reference sequence, C and D the patient’s sequence, and E and F are the subtraction plot between the
reference sequence and the patient. The black arrows indicate the detected alteration.
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diagnosis of this disorder increases in prevalence, perhaps the
genetic constructs of this disease, if present, will be better
understood. Finally, LC MS/MS is key to setting this process
in motion, as it confirms the presence of amyloidogenic
protein and classifies the type of amyloid.
MATERIALS AND METHODS
Specimen preparation, laser microdissection, and MS-based
proteomic analysis
The methods have previously been published.15,21,22 Briefly, 10-mm-
thick sections of formalin-fixed paraffin-embedded tissues were
stained with Congo red. Medulla with positive Congo red areas
viewed under fluorescent light source appeared bright red. The
Congo red deposits were identified under fluorescent light and
microdissected with LMD. Following LMD, there is a vacant space
on the slide. The microdissected material was collected into 0.5-ml
microcentrifuge tube caps containing 35 ml Tris/EDTA/0.002%
Zwittergent buffer. Microdissected fragments were digested into
tryptic peptides overnight and analyzed by liquid chromatography
electrospray tandem MS. MS raw data files were queried using three
different algorithms (Sequest, Mascot, and X!Tandem); the results
were combined and assigned peptide and protein probability scores
in Scaffold (Proteome Software, Portland, OR). For each case, a list
of proteins based on peptides identified by MS was generated.
Peptide identifications were accepted if they could be established at
greater than 90.0% probability as specified by the Peptide
Prophet algorithm.23–25 Protein identifications below the 90%
confidence level and those with single peptide identification were
not considered in our analysis. The ‘Spectra’ value indicates the total
number of mass spectrum collected on the mass spectrometer and
matched to the protein using the proteomics software. A higher
number of mass spectra is indicative of greater abundance and will
typically yield greater amino acid sequence coverage. A higher mass
spectra value also indicates a higher confidence in the protein
identification. Our clinical amyloid testing requires a minimum
number of four spectra in all samples before the protein
identification will be deemed clinically valid.
Genetic evaluation
Evaluation of mutations for familial amyloidosis (as with other
hereditary conditions) requires a blood sample for assessment of
germline mutations. This was acquired and submitted to our
Molecular Genetics Laboratory. The DNA was extracted using the
MagNaPure LC (Roche Diagnostics, Indianapolis, IN), followed by
PCR amplification using primers for apolipoprotein A-I and
apolipoprotein A-IV with universal sequencing tags attached. Next,
gel electrophoresis was performed ensuring adequate PCR product,
then the PCR product was cleaned using Agencourt AMPure XP
(Beckman Coulter Genomics, Danvers, MA) and placed on ABI3730
for sequencing by capillary electrophoresis. Results were analyzed using
the Mutation Surveyor v3.24 software (Softgenetics, State College, PA).
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